Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

"It is great news that leniolisib has achieved such positive results in this Phase III study in APDS." — Charlotte Cunningham-Rundles, M.D., Ph.D., Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗